QuidelOrtho Corporation has announced its intention to acquire full ownership of LEX Diagnostics following the anticipated 510(k) clearance by the U.S. FDA. The transaction, valued at approximately $100 million at closing, signifies a strategic shift in QuidelOrtho's molecular diagnostics strategy. As part of this realignment, QuidelOrtho plans to discontinue the development of its Savanna® platform. This move aims to strengthen the company's presence in the rapidly growing point-of-care molecular diagnostics segment. The announcement was made by Brian J. Blaser, President and CEO of QuidelOrtho, who highlighted the performance advantages and growth opportunities offered by LEX Diagnostics.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。